针对上述提问，众生药业回应称："您好！公司重视药品的国外市场机会，积极寻求国际合作。如达到 相关披露标准，公司将严格根据信息披露规则及时履行信息披露义务。谢谢！" 来源：金融界 金融界8月22日消息，有投资者在互动平台向众生药业提问："董秘你好，贵公司几个月前就在说正在积 极洽谈bd，请问目前进度如何了呢？是否有实质性的进展了呢？" ...

针对上述提问，众生药业回应称："您好！公司按照'中药为基、创新引领，聚焦特色的医药健康企 业'的战略目标定位，始终坚持以创新驱动发展，聚焦代谢性疾病、呼吸系统疾病等领域，积极推进创 新药研发。公司每年研发投入连续多年超过营业收入的8%，近三年每年研发投入均超过营业收入 10%。药品研发是一个高投入、长周期、高风险的过程，公司以保障研发项目的顺利推进为前提，根据 各研发项目的进度阶段性投入相应研发费用。研发代表的是公司的未来，公司将持续投入以研发创新引 领公司发展，构筑起中药、创新药、改良型新药、化学仿制药及原料药的多元化研发矩阵，从传统中药 企业逐步向创新型企业迈进。谢谢！"责任编辑：栎树 金融界8月22日消息，有投资者在互动平台向众生药业提问："董秘你好，贵公司目前资金是否充足，能 否支撑后续的创新药研发？" ...

Core Viewpoint - The company is developing a multi-target peptide drug, RAY0221, which is aimed at treating diabetes, obesity, and non-alcoholic fatty liver disease, currently in the preclinical research phase [1] Group 1 - The drug RAY0221 has GLP-1/GIP/GCG three-target activity [1] - The project is progressing as planned in its development [1] - The company is committed to advancing the project in an orderly manner [1]

Core Viewpoint - Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received a drug registration certificate for the innovative drug Anladiwei tablets (brand name: Anruiwei®) from the Macao SAR government, indicating a significant advancement in flu treatment options [1] Group 1 - Anladiwei tablets have shown superior results in a Phase III clinical trial against oseltamivir capsules and placebo, with significant improvements in key endpoints such as time to alleviation of flu symptoms (TTAS) and other viral indicators [1] - The median TTAS and fever relief time for Anladiwei tablets were nearly 10% shorter compared to the oseltamivir group, demonstrating its efficacy [1] - Anladiwei tablets maintain strong inhibitory effects against oseltamivir and mabosavir-resistant viral strains, providing a better treatment option for patients and addressing the issue of antiviral resistance [1] Group 2 - The approval for Anladiwei tablets to be sold in Macao is expected to benefit more flu patients, offering safe and effective treatment choices for physicians and patients alike [1]

资金流向方面，8月21日主力资金净流出6197.82万元，占流通市值的0.36%。近五个交易日主力资金累 计净流入1.09亿元，占流通市值的0.64%。 风险提示：股市有风险，投资需谨慎。 截至2025年8月21日收盘，众生药业股价报22.56元，较前一交易日下跌0.23元，跌幅1.01%。当日成交 额8.48亿元，换手率4.92%。 众生药业是一家以中药及创新药研发为主的企业，业务涵盖药品生产、销售及研发。公司近期在创新药 领域有所布局，RAY0221作为其自主研发的多靶点药物，拟用于治疗糖尿病、肥胖及非酒精性脂肪 肝。 公司8月21日在投资者互动平台表示，RAY0221目前处于临床前研究阶段，后续将按计划推进开发工 作。 ...

昂拉地韦片对奥司他韦、玛巴洛沙韦耐药病毒株保持强效抑制作用，为患者提供更优治疗选择，并且为 破解流感用药耐药困局提供了结构性优势。本次昂拉地韦片获批在澳门上市销售，有望惠及更多流感患 者，为广大医师和患者提供安全、有效的治疗选择。 昂拉地韦片与奥司他韦胶囊头对头、安慰剂对照治疗成人甲型流感的III期临床试验结果表明，昂拉地韦 片在主要终点指标七项流感症状缓解时间(TTAS)、次要终点指标包括单系统或单症状指标缓解时间、 病毒学指标(如病毒载量下降、病毒转阴时间、病毒转阴参与者比例)等均优于安慰剂组，达到统计学显 著性差异。昂拉地韦片在中位TTAS和发热缓解时间均比奥司他韦组缩短了近10%。 格隆汇8月21日丨众生药业(002317.SZ)公布，近日，广东众生药业股份有限公司控股子公司广东众生睿 创生物科技有限公司(简称"众生睿创")获得澳门特别行政区政府药物监督管理局签发的一类创新药物昂 拉地韦片(商品名：安睿威®)成药登记证书。 ...

证券代码：002317 公告编号：2025-088 广东众生药业股份有限公司 关于获得昂拉地韦片（商品名：安睿威®） 澳门成药登记证书的公告 证券代码：002317 公告编号：2025-088 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众 生睿创生物科技有限公司（以下简称"众生睿创"）获得澳门特别行政区政府药 物监督管理局签发的一类创新药物昂拉地韦片（商品名：安睿威®）成药登记证 书。现将相关情况公告如下： 一、药品的基本情况 药物名称：昂拉地韦片 商品名称：安睿威 主要成份：昂拉地韦 剂型：片剂 登记编号：MAC-07347 二、药品相关情况 昂拉地韦片（商品名：安睿威®）于 2025 年 5 月获得国家药品监督管理局 批准上市，是具有明确作用机制和全球自主知识产权的全球首款流感 RNA 聚合 酶 PB2 蛋白抑制剂，适用于成人单纯性甲型流感患者的治疗，具有快速、强效、 低耐药的特点。 昂拉地韦片与奥司他韦胶囊头对头、安慰剂对照治疗成人甲型流感的 III 期 临床试验结果表明，昂拉地韦片在 ...

Core Viewpoint - The company is developing RAY0221, a multi-target peptide drug with GLP-1/GIP/GCG activity, aimed at treating diabetes, obesity, and non-alcoholic fatty liver disease, currently in the preclinical research stage [2] Group 1 - RAY0221 is a self-developed drug by the company [2] - The drug targets three pathways: GLP-1, GIP, and GCG [2] - The project is currently in the preclinical research phase and will proceed according to the planned development schedule [2]

Company Overview - Zhongsheng Pharmaceutical closed at 22.79 yuan on August 20, down 1.04 yuan, a decrease of 4.36% from the previous trading day [1] - The opening price was 23.39 yuan, with a high of 24.34 yuan and a low of 22.50 yuan, and the trading volume reached 661,194 hands with a transaction amount of 1.537 billion yuan [1] Business Operations - Zhongsheng Pharmaceutical is primarily engaged in the manufacturing of pharmaceuticals, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, and biological drugs [1] - The company's product range covers multiple therapeutic areas, including cardiovascular, anti-infection, digestive system, and respiratory system [1] Market Activity - On the morning of August 20, Zhongsheng Pharmaceutical experienced a rapid rebound, with a rise of over 2% within 5 minutes, peaking at 24.01 yuan [1] - The net outflow of main funds on that day was 120.6993 million yuan, while the net inflow over the past five days was 14.899 million yuan [1]

Market Performance - The monkeypox concept sector declined by 0.86%, ranking among the top losers in the market, with stocks like Fuyuan Pharmaceutical and Chengyi Pharmaceutical hitting the daily limit down [1] - Notable declines were observed in Wanfu Biology, Rejing Biology, and Zhongsheng Pharmaceutical, while 23 stocks within the sector saw price increases, with Toukeng Life, Chuangyuan Technology, and New Industry leading the gains at 7.45%, 3.96%, and 1.86% respectively [1][2] Capital Flow - The monkeypox concept sector experienced a net outflow of 1.624 billion yuan, with 61 stocks facing net outflows, and 11 stocks seeing outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 212.3 million yuan, followed by Fuyuan Pharmaceutical, Wanfu Biology, and Zhongsheng Pharmaceutical with net outflows of 164.1 million yuan, 126 million yuan, and 120 million yuan respectively [2][3] Top Gainers and Losers - The top gainers in the monkeypox concept sector included Toukeng Life, which saw a net inflow of 24.68 million yuan, and Guoyao Modern with a net inflow of 2.185 million yuan [4] - Conversely, the top losers included Hanyu Pharmaceutical, Fuyuan Pharmaceutical, and Wanfu Biology, which all faced significant capital outflows [2][3]